Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection

Enrico Garaci, Giovanni Rocchi, Luigi Perroni, Cartesio D'Agostini, Fabrizio Soscia, Sandro Grelli, Antonio Mastino, Cartesio Favalli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalInternational Journal of Clinical & Laboratory Research
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1994

Fingerprint

Thymosin
Zidovudine
Virus Diseases
Viruses
Interferons
Lymphocytes
HIV
T-cells
Interferon-alpha
Antiviral Agents
Therapeutics
Health
Tissue Donors
Clinical Trials
T-Lymphocytes

Keywords

  • Combination therapy
  • Human immunodeficiency virus infection
  • Interferon-α
  • Thymosin α
  • Zidovudine

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection. / Garaci, Enrico; Rocchi, Giovanni; Perroni, Luigi; D'Agostini, Cartesio; Soscia, Fabrizio; Grelli, Sandro; Mastino, Antonio; Favalli, Cartesio.

In: International Journal of Clinical & Laboratory Research, Vol. 24, No. 1, 01.1994, p. 23-28.

Research output: Contribution to journalArticle

Garaci, Enrico ; Rocchi, Giovanni ; Perroni, Luigi ; D'Agostini, Cartesio ; Soscia, Fabrizio ; Grelli, Sandro ; Mastino, Antonio ; Favalli, Cartesio. / Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection. In: International Journal of Clinical & Laboratory Research. 1994 ; Vol. 24, No. 1. pp. 23-28.
@article{1c1d9e93632d4b3b9355297a7dd8b8e4,
title = "Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection",
abstract = "We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.",
keywords = "Combination therapy, Human immunodeficiency virus infection, Interferon-α, Thymosin α, Zidovudine",
author = "Enrico Garaci and Giovanni Rocchi and Luigi Perroni and Cartesio D'Agostini and Fabrizio Soscia and Sandro Grelli and Antonio Mastino and Cartesio Favalli",
year = "1994",
month = "1",
doi = "10.1007/BF02592405",
language = "English",
volume = "24",
pages = "23--28",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection

AU - Garaci, Enrico

AU - Rocchi, Giovanni

AU - Perroni, Luigi

AU - D'Agostini, Cartesio

AU - Soscia, Fabrizio

AU - Grelli, Sandro

AU - Mastino, Antonio

AU - Favalli, Cartesio

PY - 1994/1

Y1 - 1994/1

N2 - We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.

AB - We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.

KW - Combination therapy

KW - Human immunodeficiency virus infection

KW - Interferon-α

KW - Thymosin α

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0028249186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028249186&partnerID=8YFLogxK

U2 - 10.1007/BF02592405

DO - 10.1007/BF02592405

M3 - Article

VL - 24

SP - 23

EP - 28

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 1

ER -